Pancreatic islet cell transplantation
Defines coverage policy for autologous and allogeneic pancreatic islet cell transplantation and bioartificial pancreas devices for Cigna-administered health benefit plans, including medical necessity determinations, coding, background, literature, and related guidance. This part (1 of 2) includes policy statements, background, professional society positions, literature summaries, FDA information (including Lantidra), and coding lists.
Focused Review 09/15/2023: Updated allogeneic policy statement with clarifying language.
Annual Review 06/15/2024: No clinical policy statement changes.
Annual Review 06/15/2025: No clinical policy statement changes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.